5:28 PM
 | 
Sep 09, 2013
 |  BC Extra  |  Clinical News

Chimerix jumps on Phase III trial start for CMX001

Chimerix Inc. (NASDAQ:CMRX) gained $2.73 (17%) to $19.07 on Monday after starting the Phase III SUPPRESS trial of brincidofovir ( CMX001) to prevent cytomegalovirus (CMV) infection...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >